𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Dual inhibition of epidermal growth factor receptor and insulin-like growth factor receptor I: Reduction of angiogenesis and tumor growth in cutaneous squamous cell carcinoma

✍ Scribed by Chad E. Galer; Christina L. Corey; Zhuoying Wang; Maher N. Younes; Fernando Gomez-Rivera; Samar A. Jasser; Dale L. Ludwig; Adel K. El-Naggar; Randal S. Weber; Jeffrey N. Myers

Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
572 KB
Volume
33
Category
Article
ISSN
1043-3074

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Background

Cutaneous squamous cell carcinoma (CSCC) is the second most common nonmelanoma skin cancer. Most of the approximately 250,000 cases occurring annually in the United States are small, nonaggressive, and cured by excision alone. However, a subset of these tumors which are defined by poorly differentiated histology, large tumor size, invasion of adjacent structures, and/or regional metastases can prove resistant to treatment despite adjuvant radiotherapy and can have an increased risk of recurrence and nodal metastasis. Novel therapeutic approaches are necessary to improve the outcomes for patients with aggressive CSCC.

Methods

We analyzed the effect of targeted therapy on the growth and survival of CSCC cell lines using an anti‐insulin‐like growth factor‐I receptor (IGF‐IR) antibody, A12, alone or in combination with an anti‐epidermal growth factor receptor (EGFR) antibody, cetuximab, both in vitro and in vivo in an athymic nude mouse model of CSCC.

Results

Treatment with A12 and cetuximab inhibited the signaling pathways of IGF‐IR and EGFR and inhibited proliferation and induced apoptosis of squamous cell carcinoma (SCC) cell lines in vitro. Immunohistochemical staining revealed decreased proliferating cell nuclear antigen (PCNA), microvessel density, and increased apoptosis within the treated tumor xenografts. In addition, the administration of A12, alone or in combination with cetuximab inhibited the growth of tumors by 51% and 92%, respectively, and significantly enhanced survival in the nude mouse model of CSCC (p = .044 and p < .001, respectively).

Conclusion

These data suggest that dual treatment with monoclonal antibodies to the EGFR and IGF‐IR may be therapeutically useful in the treatment of CSCC. Β© 2010 Wiley Periodicals, Inc. Head Neck, 2011

πŸ“œ SIMILAR VOLUMES

Expression of insulin-like growth factor
Expression of insulin-like growth factor II and receptors for insulin-like growth factor II, insulin-like growth factor I and insulin in isolated and cultured rat hepatocytes
✍ Eugenia Lamas; FrΓ©dΓ©rique Zindy; Danielle Seurin; Christiane Guguen-Guillouzo; C πŸ“‚ Article πŸ“… 1991 πŸ› John Wiley and Sons 🌐 English βš– 714 KB

Insulin-like growth factor I1 is believed to play an important role in fetal growth and development. The insulin-like growth factor I1 gene expression is tissue specific and developmentally regulated. We have previously shown an enhanced level of insulin-like growth factor I1 messenger RNA and prote

Insulin-like growth factor family in mal
Insulin-like growth factor family in malignant haemangiopericytomas: the expression and role of insulin-like growth factor I receptor
✍ Paveli?, Kre?imir; Paveli?, Zlatko P.; Cabrijan, Tomislav; Karner, Ivan; Samar?i πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 235 KB πŸ‘ 2 views

Haemangiopericytoma is a rare soft tissue tumour originating from the contractile pericapillary cells. Relatively little is known about its molecular pathogenesis. To address this issue, the insulin-like growth factor family (IGFs) was analysed in 19 tumours collected from a human tumour bank networ

Binding of epidermal growth factor and i
Binding of epidermal growth factor and insulin-like growth-factor I in renal carcinoma and adjacent normal kidney tissue
✍ Fredrika Pekonen; Seppo Partanen; Eeva-Marja Rutanen πŸ“‚ Article πŸ“… 1989 πŸ› John Wiley and Sons 🌐 French βš– 659 KB

The bindin of epidermal growth factor (EGF) and insulinlike growth factor I (IGF-I) to cell membranes was determined in 14 renal cancers and in 13 normal kidney tissues adjacent to the tumors. The soluble 34K IGF binding protein (34K IGF-BP) content and the phosphotyrosyl-protein phosphatase activit

Epidermal growth factor receptor targete
Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck
✍ Mark E. Sharafinski; Robert L. Ferris; Soldano Ferrone; Jennifer R. Grandis πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 382 KB πŸ‘ 2 views

## Abstract ## Background Cumulative evidence implicates the epidermal growth factor receptor (EGFR) as an important therapeutic target in head and neck squamous cell carcinoma (HNSCC). The basis for the lack of correlation between EGFR expression in the HNSCC tumor and clinical responses to EGFR